Business Context and Reporting Period
This Form 8-K was filed by Bristol-Myers Squibb Company on September 3, 2004, reporting an event that occurred on August 11, 2004. The filing concerns a Request for Reexamination of a key patent for the antipsychotic drug Abilify (aripiprazole), which is marketed by the Company under an alliance with Otsuka Pharmaceutical Co., Ltd.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal and intellectual property event rather than financial performance data.
Material Changes and Events
- Patent Reexamination: Otsuka Pharmaceutical filed a Request for Reexamination with the USPTO regarding U.S. Patent No. 5,006,528, the basic composition of matter patent for Abilify.
- Reason for Filing: Otsuka identified an error in the original patent application where a prior art reference was cited with the wrong patent number and submitted additional citations.
- Timeline: The USPTO is expected to issue a final decision within 10 to 15 months.
- Patent Expiry: The patent currently expires in 2009 but may be extended to 2014 pending supplemental protection.
Outlook, Risks, and Management Commentary
Management and Otsuka believe the invention is patentable and expect the USPTO to reconfirm the patent's validity. However, the filing explicitly states there is no guarantee of the outcome. The primary risk is that if the patent is not reconfirmed, the Company could face an earlier-than-expected loss of market exclusivity for Abilify, leading to generic competition. This outcome would be material to the Company, as Abilify sales are expected to drive growth over the next several years. The Company holds marketing rights in the U.S. and Puerto Rico until November 2012 and in certain EU countries until June 2014.
Investor Verification Checklist
- Verify the status of the USPTO reexamination proceedings for Patent No. 5,006,528.
- Monitor the timeline for the USPTO's final decision (expected within 10-15 months of the August 2004 filing).
- Assess the potential impact on Abilify's market exclusivity and projected revenue growth if the patent is invalidated.
- Review the terms of the alliance agreement with Otsuka regarding marketing rights expiration dates.